Tannic acid mitigates the DMBA/croton oil-induced skin cancer progression in mice.
Skin cancer is the most common malignancy in the world and also one of the major causes of death worldwide. The toxic environmental pollutant 7,12-dimethylbenz[a]anthracene (DMBA) is a skin-specific carcinogen. Tannic acid (TA) is reported to be effective against various types of chemical-induced toxicities and carcinogenesis as well. In the present study, we have evaluated the therapeutic potential of tannic acid in DMBA + croton oil-induced skin cancer in Swiss albino mice. Protective effect of TA against skin cancer was evaluated in terms of antioxidant enzymes activities, lipid peroxidation, histopathological changes and expression of inflammation and early tumour markers. DMBA + croton oil causes depletion of antioxidant enzymes (p < 0.001) and elevation of early inflammatory and tumour promotional events. TA prevents the DMBA + croton oil-induced toxicity through a protective mechanism that involves the reduction of oxidative stress as well as COX-2, i-NOS, PCNA protein expression and level of proinflammatory cytokine such as IL-6 release at a very significant level (p < 0.001). It could be concluded from our results that TA attenuates DMBA + croton oil-induced tumour promotional potential possibly by inhibiting oxidative and inflammatory responses and acts as antioxidant, anti-inflammatory and antiproliferative agent.
Section of Molecular Carcinogenesis and Chemoprevention, Department of Medical Elementology and Toxicology, Faculty of Science, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi, 110062, India.
Ferial
F
Majed
Summya
S
Rashid
Abdul Quaiyoom
AQ
Khan
Sana
S
Nafees
Nemat
N
Ali
Rashid
R
Ali
Rehan
R
Khan
Syed Kazim
SK
Hasan
Syed Jafar
SJ
Mehdi
Sarwat
S
Sultana
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D029802:Croton / Q000737:chemistry; D051546:Cyclooxygenase 2 / Q000378:metabolism; D018450:Disease Progression; D004353:Drug Evaluation, Preclinical; D005260:Female; D005978:Glutathione / Q000378:metabolism; D006861:Hydrogen Peroxide / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D015227:Lipid Peroxidation; D051379:Mice; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010938:Plant Oils; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D013634:Tannins / Q000494:pharmacology* / Q000627:therapeutic use; D014969:Xanthine Oxidase / Q000378:metabolism
D016588:Anticarcinogenic Agents; D015850:Interleukin-6; D010938:Plant Oils; D018809:Proliferating Cell Nuclear Antigen; D013634:Tannins; D015127:9,10-Dimethyl-1,2-benzanthracene; D006861:Hydrogen Peroxide; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; D014969:Xanthine Oxidase; D005978:Glutathione